Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8

Size: px
Start display at page:

Download "Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8"

Transcription

1 Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group Moderately high Carboplatin dose by EDTA or creatinine clearance. If calculated using formula then AUC 6 vomiting, mucositis, alopecia (uncommon), amenorrhoea, peripheral neuropathy, diarrhoea, carcinogenesis, infertility Symptomatic treatment of side effects: Mouth care, CXR U & E s, LFTs, creatinine, urate, creatinine clearance U & E s, LFTs, creatinine After two cycles Reference: Rudd et al, J. Clin. Oncol., 23; pages rd Edition 1

2 Cisplatin/Gemcitabine Lung Cancer (non-small cell) Adjuvant, Neoadjuvant Cisplatin 50mg/m 2 1L N. Saline/2hrs Day 1, 2 Gemcitabine 1250mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility, CXR After two cycles Reference: Cardenal et al, J. Clin. Oncol., 17; pages rd Edition 2

3 Carboplatin/Vinorelbine Advanced Lung, Breast and Ovarian cancer Vinorelbine 25mg/m 2 20mls N. Saline/10mins Days 1 & 8 Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Cycle frequency: Every three weeks Total number of cycles: 4-6 Anti-emetic group Moderately high Carboplatin dose by EDTA or creatinine clearance. If calculated using formula then AUC 6 vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, fluid retention, hypersensitivity reaction, abdominal discomfort, infertility Symptomatic treatment of side effects: Mouth care, diuretics U & E s, LFTs, creatinine, urate, creatinine clearance U & E s, LFTs, creatinine Abdominal CT scan prior to fourth cycle if measurable disease present (ovarian) Reference: Cremonesi et al, Oncology, 64; pages rd Edition 3

4 MVP Lung Cancer (non-small cell) - Advanced, Palliative Mitomycin C 8mg/m 2 iv Day 1 Vinblastine 6mg/m 2 (max 10mg) iv Day 1 Cisplatin 50mg/m 2 1L N. Saline/2hrs Day 1 Cycle frequency: Every three weeks Total number of cycles: 3 Anti-emetic group High Ensure serum creatinine is within normal levels Pre & post hydration, mannitol, potassium & magnesium Blood film is normal i.e. no red cell fragmentation vomiting, mucositis, alopecia, cardiotoxicity, peripheral neuropathy, nephrotoxicity, ototoxicity, infertility, CXR Reference: Smith et al, J. Clin. Oncol., 19; pages rd Edition 4

5 MIC Lung Cancer (non-small cell) - Advanced, Palliative Mitomycin C 6mg/m 2 iv Day 1 Ifosfamide 3000mg/m 2 1L N. Saline/4hrs Day 1 Cisplatin 50mg/m 2 1L N. Saline/2hrs Day 1 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Pre & post hydration, mannitol, potassium & magnesium Mesna dose guidelines vomiting, mucositis, alopecia, peripheral neuropathy, diarrhoea, constipation, nephrotoxicity, ototoxicity, encephalopathy, carcinogenesis, infertility, CXR Re-assess after 2 cycles Reference: Cullen et al, Br. J. Cancer, 58; pages rd Edition 5

6 NP (Vinorelbine/Cisplatin) Lung Cancer (non-small cell) Adjuvant Vinorelbine 30mg/m 2 20mls N. Saline/10mins Days 1, 8, 15 & 22 Cisplatin 50mg/m 2 1L N. Saline/4hrs Days 1 & 2 Cycle frequency: Every four weeks Total number of cycles: 4 Anti-emetic group High Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility, CXR Re-assess after 2 cycles Reference: Winton et al, N. Engl. J. Med., 352; pages rd Edition 6

7 Docetaxel Lung Cancer (non-small cell) - Recurrent Docetaxel 75mg/m 2 250mls N. Saline/1hr Day 1 Cycle frequency: Every three weeks Total number of cycles: 6 Anti-emetic group Low Pre-medication dexamethasone 8 mg bd oral, for three days, starting one day prior vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, fluid retention, hypersensitivity reaction, skin rash, infertility Symptomatic treatment of side effects: Mouth care, CXR U & E s, LFTs, creatinine, urate U & E s, LFTs, creatinine Re-assess after 2 cycles Reference: Shephard et al, J. Clin. Oncol., 18; pages rd Edition 7

8 Docetaxel/Cisplatin Lung Cancer (non-small cell) Advanced, Palliative Docetaxel 75mg/m 2 250ml N. Saline/1hr Day 1 Cisplatin 75mg/m 2 1L N. Saline/4hrs Day 1 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Pre-medication dexamethasone 8mg bd oral, for three days, starting one day prior Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility, fluid retention, hypersensitivity reaction History and examination, CXR Mid-treatment: Post-treatment: Re-assess after 2 cycles Reference: Schiller et al, N. Engl. J. Med., 346; pages rd Edition 8

9 PE (Cisplatin/Etoposide) - long Lung Cancer (small cell) - Limited Cisplatin 60mg/m 2 1L N. Saline/2hrs Day 1 Etoposide 120mg/m 2 1L N. Saline/2hrs Days 1-3 Cycle frequency: Every three weeks Total number of cycles: 4 ( Anti-emetic group High Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility Re-assess prior to third cycle Reference: Turrisis et al, N. Engl. J. Med., 340; pages rd Edition 9

10 PE (Cisplatin/Etoposide) - short Lung Cancer (small cell) - Limited Cisplatin 60mg/m 2 1L N. Saline/2hrs Day 1 Etoposide 120mg/m 2 1L N. Saline/2hrs Day 1 Etoposide 100mg bd oral Days 2 & 3 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Pre & post hydration, mannitol, potassium & magnesium vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, carcinogenesis, infertility Re-assess prior to third cycle Reference: Evans et al, Ann. Intern. Med., 107; pages rd Edition 10

11 Carboplatin/Etoposide - long Lung Cancer - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Etoposide 100mg/m 2 500mls N. Saline/2hrs Days 1-3 Cycle frequency: Every three weeks Total number of cycles: 4-6 Anti-emetic group Moderately high Etoposide 100mg bd oral may be substituted on days 2 & 3 Carboplatin dose by EDTA or creatinine clearance. If calculated using formula then AUC 6 vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, diarrhoea, carcinogenesis, infertility Re-assess prior to third cycle Reference: Skarlos et al, Ann. Oncol., 5; pages rd Edition 11

12 Carboplatin/Etoposide - short Lung Cancer - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Etoposide 100mg/m 2 500mls N. Saline/2hrs Day 1 Etoposide 100mg bd oral Days 2 & 3 Cycle frequency: Every three weeks Total number of cycles: 4-6 Anti-emetic group Moderately high Carboplatin dose by EDTA or creatinine clearance. If calculated using formula then AUC 6 vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, nephrotoxicity, diarrhoea, carcinogenesis, infertility Re-assess prior to third cycle Reference: Skarlos et al, Ann. Oncol., 5; pages rd Edition 12

13 CAV (Cyclophosphamide/Doxorubicin/Vincristine) Lung Cancer (small cell) Palliative Cyclophosphamide 1,000mg/m 2 iv Day 1 Doxorubicin 50mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Cycle frequency: Every three weeks Total number of cycles: 6 Anti-emetic group Moderately high vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, haemorrhagic cystitis, constipation, carcinogenesis, infertility, CXR U & E s, LFTs, creatinine, urate U & E s, LFTs, creatinine Re-assess prior to fourth cycle Reference: Evans et al, Ann. Intern. Med., 107; pages rd Edition 13

14 Oral Etoposide Lung Cancer (small cell) - Palliative Etoposide 100mg od oral Days 1-10 (14) Cycle frequency: Every three weeks Total number of cycles: 6 Anti-emetic group Mild Start with 10 day course (total dose 1000 mg) Toxicities: Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea, mucositis, alopecia, carcinogenesis, infertility Symptomatic treatment of side effects: Mouth care, CXR U & E s, LFTs, creatinine, urate U & E s, LFTs, creatinine Re-assess after every two cycles Reference: Slevin, J. Clin. Oncol., 8; pages rd Edition 14

Cycle frequency: Every three weeks Total number of cycles: 6

Cycle frequency: Every three weeks Total number of cycles: 6 Carboplatin/Paclitaxel Ovarian Cancer Adjuvant, Advanced Paclitaxel 175mg/m 2 500mls 5% dex/3hrs Day 1 Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Anti-emetic group - Moderately high Paclitaxel given first

More information

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 Doxorubicin/Cisplatin Osteosarcoma - neoadjuvant Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 (3 before surgery) Ensure adequate renal function Pre & post-hydration,

More information

Cycle frequency: Every three weeks Total number of cycles: 3 or 4

Cycle frequency: Every three weeks Total number of cycles: 3 or 4 BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs

More information

Cycle frequency: Every four weeks Total number of cycles: 6-8

Cycle frequency: Every four weeks Total number of cycles: 6-8 Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and

More information

Cycle frequency: Every three weeks Total number of cycles: 4 (Adjuvant) 6 (Palliative)

Cycle frequency: Every three weeks Total number of cycles: 4 (Adjuvant) 6 (Palliative) AC (Doxorubicin/Cyclophosphamide) Breast Cancer Adjuvant, Palliative Doxorubicin 60mg/m 2 iv Day 1 Cyclophosphamide 600mg/m 2 iv Day 1 Cycle frequency: Every three weeks Total number of cycles: 4 (Adjuvant)

More information

Network Chemotherapy Regimens

Network Chemotherapy Regimens Network Chemotherapy Regimens Lung Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.org.uk. Any correspondence about the protocols

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

CISPLATIN with Radical XRT Cancer of the Cervix

CISPLATIN with Radical XRT Cancer of the Cervix CISPLATIN with Radical XRT Cancer of the Cervix Background: First line treatment of cervical cancer with concurrent radiotherapy (curative intent), including patients: - With locally advanced cervical

More information

Lymphoblastic Lymphoma Burkitt s Lymphoma. Core: Standard therapy; a regimen widely used by most Regional Cancer Centres in this disease site

Lymphoblastic Lymphoma Burkitt s Lymphoma. Core: Standard therapy; a regimen widely used by most Regional Cancer Centres in this disease site A REGIMEN NAME MAGRATH PROTOCOL Chemotherapy Cancer Lymphoblastic Lymphoma Burkitt s Lymphoma Curative Intent Regimen Category Rationale and Indication Core: Standard therapy; a regimen widely used by

More information

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed

More information

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient

More information

Thames Valley Chemotherapy Regimens

Thames Valley Chemotherapy Regimens Chemotherapy Regimens Lung Cancer Notes from the editor These regimens are available on the Network website www.tvcn.org.uk. Any correspondence about the regimens should be addressed to: Sally Coutts,

More information

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility

More information

Breast Pathway Group Pertuzumab in Advanced Breast Cancer

Breast Pathway Group Pertuzumab in Advanced Breast Cancer Breast Pathway Group Pertuzumab in Advanced Breast Cancer Indication: Regimen details: First line treatment of locally advanced or metastatic breast cancer National Cancer Drug Fund criteria: Locally advanced

More information

Regimen: Gemcitabine & Carboplatin for NSCLC

Regimen: Gemcitabine & Carboplatin for NSCLC Regimen: Gemcitabine & Carboplatin for NSCLC ICD10 codes Codes pre-fixed with C34. Indications Regimen details First-line chemotherapy for advanced (stage IIIB/IV) non-small cell lung cancer (NICE CG121)

More information

Cetuximab, Cisplatin and Fluorouracil (head and neck)

Cetuximab, Cisplatin and Fluorouracil (head and neck) Cetuximab, Cisplatin and Fluorouracil (head and neck) Indication First line treatment of recurrent or metastatic head and neck squamous cell cancer. ICD-10 codes Codes prefixed with C00-C13 Regimen details

More information

Gemcitabine, Methylprednisolone and Cisplatin (GEM-P) Regimen

Gemcitabine, Methylprednisolone and Cisplatin (GEM-P) Regimen Gemcitabine, Methylprednisolone and Cisplatin (GEM-P) Regimen Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A

More information

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) Protocol Code Tumour Group Contact Physician UGUTIP Genitourinary Dr.

More information

Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer

Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment of breast cancer Regimen details: Doxorubicin 60mg/m 2 IV Day 1 Cyclophosphamide

More information

TPF (Docetaxel, cisplatin and fluorouracil) for head and neck cancer

TPF (Docetaxel, cisplatin and fluorouracil) for head and neck cancer Regimen: TPF (Docetaxel, cisplatin and fluorouracil) for head and neck cancer Indications Neo-adjuvant treatment prior to definitive chemo-radiotherapy for locally advanced head and neck squamous cell

More information

EC TH Neoadjuvant Breast Cancer

EC TH Neoadjuvant Breast Cancer EC TH Neoadjuvant Breast Cancer Background: Neoadjuvant chemotherapy for inoperable locally advanced, inflammatory breast cancer or to downsize tumour prior to surgery. For patients with HER2 positive

More information

Thames Valley. Thames Valley Chemotherapy Regimens Breast Cancer

Thames Valley. Thames Valley Chemotherapy Regimens Breast Cancer Chemotherapy Regimens Breast Cancer Notes from the editor These regimens are available on the Network website www.tvscn.nhs.uk Any correspondence about the regimens should be addressed to: Sally Coutts,

More information

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine

More information

Guidelines for the Use of Anti-Emetics with Chemotherapy

Guidelines for the Use of Anti-Emetics with Chemotherapy Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting

More information

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol FEC-DH in the adjuvant treatment of Breast Cancer (BRWOS- 031/1) Indication Adjuvant chemotherapy for HER2+ve Early Breast Cancer Eligibility

More information

Thames Valley. Thames Valley Chemotherapy Regimens Upper Gastrointestinal Cancer

Thames Valley. Thames Valley Chemotherapy Regimens Upper Gastrointestinal Cancer Chemotherapy Regimens Upper Gastrointestinal Cancer Notes from the editor These protocols are available on the Network website www.tvcn.nhs.uk. Any correspondence about the protocols should be addressed

More information

Thames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer

Thames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer Network Chemotherapy Protocols Breast Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.nhs.uk. Any correspondence about the protocols

More information

Northern Ireland Cancer Network. Lung. Systemic Anti-Cancer Therapy. Protocols

Northern Ireland Cancer Network. Lung. Systemic Anti-Cancer Therapy. Protocols Northern Ireland Cancer Network Lung Systemic Anti-Cancer Therapy Protocols V1.1 Northern Ireland Cancer Network Lung Systemic Anti-Cancer Therapy Protocols Contents Contents... 1 Authorisation of Lung

More information

Carboplatin/Gemcitabine Combination in Advanced NSCLC

Carboplatin/Gemcitabine Combination in Advanced NSCLC Review Article [1] July 01, 2004 By Sakkaraiappan Ramalingam, MD [2] and Chandra P. Belani, MD [3] The treatment of advanced non small-cell lung cancer (NSCLC) has evolved rapidly over the past few years.

More information

Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer

Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer Regimen: Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer Indication Approved for the treatment of early and locally advanced breast cancer in

More information

CTD (Cyclophosphamide, Thalidomide and Dexamethasone)

CTD (Cyclophosphamide, Thalidomide and Dexamethasone) MCCN Ref MMCTD OPCS Proc X71.1 OPCS Del X73.1 Haematology Chemotherapy Protocol CTD (Cyclophosphamide, Thalidomide and Dexamethasone) Indications Multiple Myeloma (newly diagnosed and relapsed / refractory

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Carboplatin/Gemcitabine Combination in Advanced NSCLC

Carboplatin/Gemcitabine Combination in Advanced NSCLC Page 1 of 9 CancerNetwork Members: Login Register CancerNetwork Powered by SearchMed PUBLICATIONS NEWS PODCASTS TOPICS BLOGS NURSES PATIENTS JOBS Home» ONCOLOGY. Vol. 18 No. 8 5 EMAIL PRINT PDF REPRINT

More information

BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN)

BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN) BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician BRAJDCARBT Breast Dr. Susan Ellard SUGGESTED

More information

Adjuvant Chemotherapy 1. Vinorelbine-25/Cisplatin-80 (chemo alone) CTIS 1722 4 2. Gemcitabine-1250/Carboplatin-5AUC CTIS 1601 5

Adjuvant Chemotherapy 1. Vinorelbine-25/Cisplatin-80 (chemo alone) CTIS 1722 4 2. Gemcitabine-1250/Carboplatin-5AUC CTIS 1601 5 LUNG CANCER Section by: Dr Conrad Lewanski, Dr Danielle Power, Dr Tom Newsom-Davis Version; Lung Cancer Regimens v4.3 NWLCN 20Feb12 Section last reviewed: 1 st July 2011 Section last corrected: 20 th February

More information

AC-Docetaxel: Doxorubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer

AC-Docetaxel: Doxorubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer AC-Docetaxel: Doxubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer Indication: Neoadjuvant therapy f high risk and fit Breast Cancer patients, suitable f a taxane containing regimen AC Regimen

More information

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma

More information

NORDIC. Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue)

NORDIC. Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue) NORDIC C) CODOX (R) CODOX M/ (R) IVAC Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue) ICD-10 code C83.13 Regimen details (R) maxi-chop

More information

Carboplatin Dosing: Area Under the Controversy. Kyle LaPorte, PharmD.

Carboplatin Dosing: Area Under the Controversy. Kyle LaPorte, PharmD. Carboplatin Dosing: Area Under the Controversy Kyle LaPorte, PharmD. Disclosure No relevant financial or non-financial conflicts of interest exist between the presenter and information discussed in this

More information

About chemotherapy for lung cancer

About chemotherapy for lung cancer About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

More information

Breast Cancer. Breast Cancer Page 1

Breast Cancer. Breast Cancer Page 1 Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or

More information

Relapsed or Refractory Hodgkin s and Non-Hodgkin s Lymphoma. 375mg/m 2

Relapsed or Refractory Hodgkin s and Non-Hodgkin s Lymphoma. 375mg/m 2 Regimen : (R)-GIFOX Indication Relapsed or Refractory Hodgkin s and Non-Hodgkin s Lymphoma Regimen details Age < 65 years This is NOT a NICE-approved indication for rituximab. Please ensure that this regimen

More information

GP AND COMMUNITY GUIDELINES FOR THE TREATMENT OF CHEMOTHERAPY COMPLICATIONS: Circulation Version Author Date

GP AND COMMUNITY GUIDELINES FOR THE TREATMENT OF CHEMOTHERAPY COMPLICATIONS: Circulation Version Author Date GP AND COMMUNITY GUIDELINES FOR THE TREATMENT OF CHEMOTHERAPY COMPLICATIONS: Circulation Version Author Date CB, MT, CH, draft CDikken 18 October 2010 KW, JS, SD Chemo group Final 10 CDikken November 29

More information

Chemotherapy for lung cancer

Chemotherapy for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 8. Contents Chemoradiation Small cell lung cancer

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

ENDOMETRIAL CANCER: SYSTEMIC THERAPIES

ENDOMETRIAL CANCER: SYSTEMIC THERAPIES ENDOMETRIAL CANCER: SYSTEMIC THERAPIES David A. Iglesias, MD, MS Assistant Professor, Virginia Tech Carilion School of Medicine Carilion Clinic Gynecologic Oncology OBJECTIVES Review systemic chemotherapies

More information

London Cancer. Mesothelioma Lung Protocols

London Cancer. Mesothelioma Lung Protocols London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta

More information

Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Indication: Neoadjuvant or adjuvant therapy in node positive patients. Also considered in

More information

Breast, lung, renal, bone metastases

Breast, lung, renal, bone metastases Nausea and vomiting: Introduction: There are a multitude of different causes for nausea and vomiting in patients with cancer. The cancer itself can cause emesis and the treatment of cancer can also cause

More information

Regimen: Gemcitabine-Capecitabine (GEMCAP) for Pancreatic Cancer

Regimen: Gemcitabine-Capecitabine (GEMCAP) for Pancreatic Cancer Regimen: Gemcitabine-Capecitabine (GEMCAP) for Pancreatic Cancer Indication Regimen detail Administration First line palliative therapy for locally advanced or metastatic or relapsed disease Day Drug Dose

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

1. Acute Myeloid Leukaemia Hyper-CVAD/MA. Indication

1. Acute Myeloid Leukaemia Hyper-CVAD/MA. Indication 1. Acute Myeloid Leukaemia 1.13 Hyper-CVAD/MA Indication Mantle-cell lymphoma (diffuse, nodular or blastic variants). Hyper-CVAD/MA has also been used in adult B-cell Acute Lymphoblastic Leukaemia. Relapsed

More information

FEC-D Regimen. FEC-D+TRAS Regimen FEC-D FEC-D+TRAS. A - Regimen Name. Disease Site Breast. Adjuvant. Regimen Category. Evidence-Informed :

FEC-D Regimen. FEC-D+TRAS Regimen FEC-D FEC-D+TRAS. A - Regimen Name. Disease Site Breast. Adjuvant. Regimen Category. Evidence-Informed : Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended

More information

DT- PACE chemotherapy for myeloma

DT- PACE chemotherapy for myeloma Patient information DT- PACE chemotherapy for myeloma Your doctors have suggested that you are likely to benefit from chemotherapy treatment. They are recommending a standard form of treatment called DT-PACE

More information

Combination Cancer Chemotherapy Regimens

Combination Cancer Chemotherapy Regimens Guide to Combination Cancer Chemotherapy Regimens Dominic A. Solimando, Jr. J. Aubrey Waddell A Thomas Land Publication CONTENTS ABBREVIATIONS...ix INTRODUCTION...xi REGIMENS 1. BREAST Cyclophosphamide,

More information

Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer

Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer Indication Adjuvant treatment for node positive early breast cancer This protocol is subject to local

More information

Cyclophosphamide, Lenalidomide (Revlimid ) & Dexamethasone (CRD) for relapsed Multiple Myeloma Page 1 of 5

Cyclophosphamide, Lenalidomide (Revlimid ) & Dexamethasone (CRD) for relapsed Multiple Myeloma Page 1 of 5 for relapsed Multiple Myeloma Page 1 of 5 Indication: Relapsed Multiple Myeloma Regimen details: Lenalidomide 25 mg od orally Days 1 to 21 Dexamethasone 20mg od orally Days 1, 8, 15, 22 Cyclophosphamide

More information

More than half of all lung cancer patients present with. New Combinations in the Treatment of Lung Cancer* A Time for Optimism

More than half of all lung cancer patients present with. New Combinations in the Treatment of Lung Cancer* A Time for Optimism New Combinations in the Treatment of Lung Cancer* A Time for Optimism Paul A. Bunn, Jr., MD; and Karen Kelly, MD Strides have been made in the treatment of lung cancer in the last decade that warrant a

More information

BRAVPTRAD. Protocol Code: Breast. Tumour Group: Dr. Stephen Chia. Contact Physician:

BRAVPTRAD. Protocol Code: Breast. Tumour Group: Dr. Stephen Chia. Contact Physician: BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour

More information

Nab-Paclitaxel (Abraxane ) and Gemcitabine 28 day

Nab-Paclitaxel (Abraxane ) and Gemcitabine 28 day Nab-Paclitaxel (Abraxane ) and Gemcitabine 28 day INDICATIONS FOR USE: INDICATION Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma

More information

Docetaxel, Doxorubicin & Cyclophosphamide (TAC) for. Early Breast Cancer

Docetaxel, Doxorubicin & Cyclophosphamide (TAC) for. Early Breast Cancer Regimen: Docetaxel, Doxubicin & Cyclophosphamide (TAC) f Early Breast Cancer Indication Adjuvant chemotherapy f node-positive early breast cancer (NICE CG 80) Adjuvant chemotherapy f high risk node-negative

More information

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, FACT SHEET BRANDED/GENERIC NAME: ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) ABRAXANE is an albumin-bound form of paclitaxel with a

More information

Dr P Savage Date Review date: October 2015. Gemcitabine Regimens 1. Gemcitabine-1250/Cisplatin-70 D1+8 CTIS 1695 2

Dr P Savage Date Review date: October 2015. Gemcitabine Regimens 1. Gemcitabine-1250/Cisplatin-70 D1+8 CTIS 1695 2 BLADDER CANCER / TRANSITIONAL CELL CARCINOMA Section by: Dr Philip Savage, Professor Jonathan Waxman, Dr Alison Falconer, Dr Simon Stewart. Version: Bladder Cancer/TCC Regimens Approved v7.01 NWLCN 15Oct13

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CEOP.DOC CONTROLLED DOC NO: HCCPG B22 CSIS Regimen Name: R-CEOP. R-CEOP Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CEOP.DOC CONTROLLED DOC NO: HCCPG B22 CSIS Regimen Name: R-CEOP. R-CEOP Regimen R-CEOP Regimen Available for Routine Use in Burton in-patient Derby in-patient (First cycle if bulky disease & risk of tumour lysis syndrome) Burton day-case Derby day-case Burton community Derby community

More information

Hydration Protocol for Cisplatin Chemotherapy

Hydration Protocol for Cisplatin Chemotherapy Betsi Cadwaladr University Health Version: 1.3 CSPM2 Hydration Protocol for Cisplatin Chemotherapy Date to be reviewed: July 2018 No of pages: 9 Author(s): Tracy Parry-Jones Author(s) title: Lead Cancer

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy in malignant mesothelioma Annals of Oncology 9: 9-7, 998. 998 Khmer Academic Publishers. Printed in the Netherlands Original article Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy

More information

Intraperitoneal therapy in Ovarian Cancer

Intraperitoneal therapy in Ovarian Cancer Intraperitoneal therapy in Ovarian Cancer Carol Josephs-Cowan, NP Division of Gynecologic Oncology Chao Family Comprehensive Cancer Center University of California Irvine Female Cancers in USA 2006 New

More information

What s New With HER2?

What s New With HER2? What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

BCCA Protocol for Primary Treatment of Metastatic or Recurrent Squamous Cancer of the Cervix with Bevacizumab, CARBOplatin and PACLitaxel

BCCA Protocol for Primary Treatment of Metastatic or Recurrent Squamous Cancer of the Cervix with Bevacizumab, CARBOplatin and PACLitaxel BCCA Protocol for Primary Treatment of Metastatic or Recurrent Squamous Cancer of the Cervix with Bevacizumab, CARBOplatin and PACLitaxel Protocol Code Tumour Group Contact Physician GOCXCATB Gynecologic

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each single-dose

More information

Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma

Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma Pre-HCT Treatment for Hodgkin s / Non-Hodgkin s Lymphoma This appendix is intended to provide additional information on: Common pre-hct treatments for lymphoma, Lines of therapy, Cycles, and How to report

More information

PREMEDICATIONS: Agent(s) Dose Route Schedule

PREMEDICATIONS: Agent(s) Dose Route Schedule BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group

More information

Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer

Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer REVIEW ARTICLE Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer Eckart Laack, Carsten Bokemeyer, Dieter Kurt Hossfeld SUMMARY Introduction: In non-small cell lung cancer (NSCLC)

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

PPPO FOR THE TREATMENT OF BURKITT LYMPHOMA AND LEUKEMIA. LYCODOX-M (Magrath A) + R (rituximab) [To be used before LYIVAC (Magrath B) + R]

PPPO FOR THE TREATMENT OF BURKITT LYMPHOMA AND LEUKEMIA. LYCODOX-M (Magrath A) + R (rituximab) [To be used before LYIVAC (Magrath B) + R] Page 1 of 6 PATIENT S NAME: PPPO FOR THE TREATMENT OF BURKITT LYMPHOMA AND LEUKEMIA LYCODOX-M (Magrath A) + R (rituximab) [To be used before LYIVAC (Magrath B) + R] LAST NAME FIRST NAME INITIAL DIAGNOSIS:

More information

Landmark Trials in Ovarian Cancer

Landmark Trials in Ovarian Cancer Landmark Trials in Ovarian Cancer Where we ve been and where we re headed Erin E. Stevens, MD Gynecologic Oncology Billings Clinic Cancer Center February 28, 2015 Health Care, Education and Research www.billingsclinic.com

More information

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral)

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral) Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral) Indication CLL 1st line as per NICE TAG 174 CLL (relapsed) as per NICE TAG 193 Regimen details Day Drug Dose Route Cycle 1 1 Rituximab 375mg/m

More information

Intraperitoneal Chemo An interesting Concept or a New Standard for Treatment of Ovarian Cancer? Christa Slatnik BN NP Gyne-Oncology Cancer Care

Intraperitoneal Chemo An interesting Concept or a New Standard for Treatment of Ovarian Cancer? Christa Slatnik BN NP Gyne-Oncology Cancer Care Intraperitoneal Chemo An interesting Concept or a New Standard for Treatment of Ovarian Cancer? Christa Slatnik BN NP Gyne-Oncology Cancer Care Manitoba Outline Ovarian Cancer Types Current Standard IV

More information

Regimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen)

Regimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen) Regimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen) Indications This is NOT a NICE-approved treatment. Please ensure that this regimen is locally

More information

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-Intravenous)

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-Intravenous) Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-Intravenous) Indication CLL 1st line as per NICE TAG 174 CLL (relapsed) as per NICE TAG 193 Note: this protocol should only be used where FCR-oral

More information

Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD]

Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD] Approved Haematology Chemotherapy Protocol Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD] MCCN Ref OPCS Proc OPCS Del CLFLUD X70.5 X72.3 IV CLFC X70.4 X72.2 IV X73.1 O CLFCR X71.5 X72.1 LYFMD

More information

1.1 Title: Generic Chemotherapy Protocol Guidelines

1.1 Title: Generic Chemotherapy Protocol Guidelines 1.1 Title: Generic Chemotherapy Protocol Guidelines 1.2 Summary of the policy s objectives: This guidance is intended to be used by all health-care professionals involved in the prescribing and delivery

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage

More information

Progress in Pancreatic Cancer

Progress in Pancreatic Cancer Progress in Pancreatic Cancer Gina Vaccaro, MD OHSU Medical Oncology September 2014 1 Anatomy of the pancreas DePinho, Nature Reviews, 2002 Pancreatic tumor types Ductal adenocarcinoma (>85%) Acinar cell

More information

LUNG CANCER TREATMENT REGIMENS (Part 1 of 8)

LUNG CANCER TREATMENT REGIMENS (Part 1 of 8) LUNG CANCER TREATMENT S (Part 1 of 8) Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration,

More information

NCCP Chemotherapy Protocol. Cabazitaxel and Prednisolone

NCCP Chemotherapy Protocol. Cabazitaxel and Prednisolone Cabazitaxel and Prednisolone INDICATIONS FOR USE: INDICATION Cabazitaxel is indicated in combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate

More information

Treatment of Small Cell Lung Cancer

Treatment of Small Cell Lung Cancer Chapter 5 Treatment of Small Cell Lung Cancer Ariel Lopez-Chavez MD, MS Introduction There are two main types of lung cancer, non-small cell lung cancer and small cell lung cancer. 1 It is important that

More information

Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda ))

Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda )) Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda )) Indication Regimen details Administration First line palliative treatment for locally advanced, inoperable oesophago-gastric cancer for

More information

Principles of Cancer Therapy

Principles of Cancer Therapy 1 Principles of Cancer Therapy Professor Mark McKeage Dept of Pharmacology & Clinical Pharmacology The University of Auckland 2 Cancer in New Zealand Cancer is a common clinical problem in NZ 21,050 new

More information

Chemotherapy for non-small cell lung cancer

Chemotherapy for non-small cell lung cancer Chemotherapy for non-small cell lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 3. Contents

More information

Board Certification Study Timeline: BCOP 10-Month Calendar

Board Certification Study Timeline: BCOP 10-Month Calendar Board Certification Study Timeline: BCOP 10-Month Calendar BCOP Best Practices 10-Month Calendar The American Society of Health-System Pharmacists New Practitioners Forum (NPF) has developed this guidance

More information

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction: Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer

More information

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Indication: Neoadjuvant or adjuvant therapy for elderly and frail patients with breast

More information

Intravenous Cyclophosphamide for Renal Patients. Protocol

Intravenous Cyclophosphamide for Renal Patients. Protocol Intravenous Cyclophosphamide for Renal Patients Protocol 1. Patients will have counselling and receive a patient information sheet from their nephrologist prior to their first infusion at Ambulatory Care.

More information

White Paper: RDI Calculator

White Paper: RDI Calculator NearSpaceMedical White Paper: RDI Calculator Author: TJD Last updated: 7.19.2011 Version: 5 What is RDI? Relative Dose Intensity (RDI) is the amount of a particular chemotherapy given over a specific time

More information

NCCP Chemotherapy Protocol. Afatinib Monotherapy

NCCP Chemotherapy Protocol. Afatinib Monotherapy Afatinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

More information